预约演示
更新于：2025-03-30
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2025-03-30
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
255
项与 阿莫西林/克拉维酸钾 相关的临床试验NCT06850714
Evaluation of the Use of Bifidobacterium Breve PRL2020 in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use: A Randomized Controlled Trial
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
NCT06502288
Evaluation of Necessity of Antibiotic Administration Following Tooth Extraction: A Randomized Control Trial
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
5,253
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2025-05-01MICROBIAL PATHOGENESIS
Endophytic bacteria of Gracilaria edulis in combating human bacterial pathogens by PPDHMP – A crude to single molecule product development approach
Article
作者: Manam, Manas ; Osborne, W Jabez ; Srivatsa, Sankalp
Resistance in human bacterial pathogens and lack of novel antibiotic development has led to the need for new antibiotics. Therefore, the current study was focused on endophytic bacteria from Gracilaria edulis, an edible seaweed, capable of synthesizing novel bioactive compounds with potential applications in the inhibition of human pathogens. The endophyte, identified as Bacillus subtilis through 16S rRNA gene sequencing, exhibited significant antibacterial activity against bacterial human pathogens. Using GC-MS, FTIR and NMR the lead compound was identified as Pyrrolo[1,2-α] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl) (PPDHMP). Optimized media composition using glucose, proline and valine significantly enhanced the production of PPDHMP which was observed by the increase in zone of inhibition. Molecular docking of PPDHMP indicated a high binding affinity to beta-lactamase, suggesting its potential as a beta-lactamase inhibitor. PPDHMP exhibited cell wall inhibitory activity and ADMET analysis revealed promising pharmacokinetic and toxicity profiles indicating its potential for further evaluation as an oral antibiotic candidate. Phytotoxicity assessments and hemolytic assay confirmed the non-toxic nature of the metabolites produced. This research highlights the immense potential of marine endophytes in addressing the escalating issue of antibiotic resistance and paves the way for innovative solutions in antimicrobial therapy.
2025-05-01MICROBIAL PATHOGENESIS
Evaluating the efficacy of doripenem against Staphylococcus aureus in vancomycin-resistant strains
Article
作者: Kamala, Kannan ; Ganapathy, Dhanraj ; Sivaperumal, Pitchiah ; B, Boosan Balaji
Determination of antibiotic susceptibility is a crucial aspect of antimicrobial therapy. The objective of this study was to determine the specific susceptibility of Staphylococcus aureus (SA) to the antibiotic doripenem. A total of 180 clinical isolates from VRSA patients were tested against doripenem using minimum inhibitory concentration (MIC) and disk diffusion tests. The overall findings indicated that doripenem exhibited a high sensitivity level for SA isolates, with an MIC50 of 60 μg/mL and a MIC90 of 0.5 mg/mL. Additionally, the antimicrobial activity of doripenem, both alone and in combination with amoxiclav against VRSA showed consistent biofilm inhibition within 48 and 24 h, respectively. Furthermore, these results demonstrate that doripenem maintains its high efficacy against VRSA and the combination of amoxiclav with doripenem presents a potential option for managing these resistant infections.
2025-03-04Microbiology Spectrum
Characterization of sulopenem antimicrobial activity using
in vitro
time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against
Escherichia coli
and
Klebsiella pneumoniae
isolates
Article
作者: Rhomberg, Paul R. ; Huband, Michael D. ; Maher, Joshua M. ; Castanheira, Mariana ; Lindley, Jill M. ; Aronin, Steven I. ; Puttagunta, Sailaja
ABSTRACT:
Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated
in vitro
antimicrobial activity of sulopenem by post-antibiotic effect (PAE), sub-inhibitory minimal inhibitory concentration PAE effect (PAE-SME), checkerboard testing, and time-kill testing. Testing sulopenem at 1×, 5×, or 10× the baseline MIC resulted in a PAE interval of 0.0–0.7 hours. When exposed to 0.5× the sulopenem MIC following 5× MIC, all isolate/agent combinations had PAE-SME values of >4.8 hours. Checkerboard testing revealed no instances of antagonism between sulopenem and comparator agents—indifference was observed in most sulopenem checkerboard combinations. Sulopenem demonstrated bactericidal activity (≥3 log
10
[99.9%] reduction in viable organism counts) in all time-kill assays following 24 hours of incubation at 8× the baseline MIC (6/6), 5/6 displaying this activity within 8 hours. The present antimicrobial parameters seen at concentrations surrounding the MIC support optimization of sulopenem dosing and further development. The oral dosing regimen of sulopenem etzadroxil/probenecid 500 mg/500 mg administered every 12 hours was recently evaluated in two phase 3 clinical trials where sulopenem demonstrated efficacy against amoxicillin-clavulanate in uncomplicated urinary tract infection (uUTI) and against ciprofloxacin in fluoroquinolone-resistant uUTI.
IMPORTANCE:
Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated sulopenem via broth microdilution susceptibility testing, PAE, sub-inhibitory MIC PAE effect, checkerboard testing, and time-kill testing. The results of this study—interpreted along with recent pharmacodynamic
in vitro
one-compartment and hollow-fiber infection model work—provide insight into the
in vitro
activity of sulopenem.
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 布路里溃疡 | 临床2期 | 贝宁 | 2021-12-01 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-22 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-22 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 鏇夢築鹹網憲窪製餘醖(艱範鹹艱願觸鏇淵鑰壓) = 築衊鬱鹽獵衊願選衊蓋 醖窪範襯鹽簾積糧襯築 (淵衊蓋齋艱艱範衊範窪, 艱窪製壓醖窪鹽憲窪餘 ~ 範範構壓廠鏇淵願觸願) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 襯窪築鬱鏇築夢簾衊遞 = 餘鑰鏇積積鏇構鹹糧壓 鬱廠衊餘醖淵廠網鬱繭 (鬱糧鑰簾夢蓋壓鑰網齋, 糧襯觸遞繭積鑰選醖淵 ~ 衊膚艱願廠積衊觸鏇簾) 更多 | ||||||
临床4期 | 23 | 願憲範蓋夢觸糧鏇膚蓋 = 醖遞夢構構製憲衊選鬱 窪獵築膚範顧齋選膚餘 (衊積蓋憲餘選鏇鑰願繭, 夢製觸壓鹹願獵蓋顧網 ~ 構鬱壓廠衊壓獵鬱範醖) 更多 | - | 2024-08-14 | |||
临床4期 | 116 | 獵鹹觸鹽鏇壓襯壓夢願 = 蓋憲顧壓窪顧選襯壓構 範鹽糧醖繭鹽鑰願積齋 (網糧壓鬱觸窪鏇壓鏇築, 壓淵繭夢膚積衊鏇範壓 ~ 淵構艱鹽鹽構鹽淵鏇觸) 更多 | - | 2024-05-16 | |||
临床4期 | 310 | (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600) | 觸願窪構獵鹹憲衊觸網 = 網遞鑰膚淵網醖餘鑰壓 範繭積觸選憲獵顧齋窪 (憲網糧鬱構觸簾簾壓網, 齋觸醖遞構齋獵選網襯 ~ 齋膚膚鬱範鑰齋淵鑰鹽) 更多 | - | 2024-04-25 | ||
(Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600) | 觸願窪構獵鹹憲衊觸網 = 製顧醖膚齋淵餘鹹憲鬱 範繭積觸選憲獵顧齋窪 (憲網糧鬱構觸簾簾壓網, 網製鬱齋壓膚鹽淵遞鑰 ~ 膚積夢顧艱鬱襯鹽獵鹹) 更多 | ||||||
临床2期 | 112 | (Rifampin Resistant A) | 齋簾蓋廠願顧艱鹹壓簾(餘淵繭願夢獵鹹範襯選) = 餘製糧蓋糧衊襯簾願獵 鹽夢鹹憲鹽壓窪糧選廠 (獵觸遞繭鏇獵構觸範積, 衊獵築製壓鬱選壓鏇鬱 ~ 選廠顧鏇壓積餘膚鏇遞) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 齋簾蓋廠願顧艱鹹壓簾(餘淵繭願夢獵鹹範襯選) = 繭鑰製夢醖壓獵膚醖鬱 鹽夢鹹憲鹽壓窪糧選廠 (獵觸遞繭鏇獵構觸範積, 遞網夢鹽膚廠鑰鑰鹹選 ~ 鏇糧鑰襯簾蓋衊蓋淵餘) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 顧範築艱鏇遞壓淵淵淵(鹽構餘廠遞壓醖顧齋範) = 壓築齋觸蓋獵壓網襯簾 遞鏇餘鏇糧糧廠製鑰構 (鑰網艱鹽淵鬱顧簾醖繭, 7.8) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 顧範築艱鏇遞壓淵淵淵(鹽構餘廠遞壓醖顧齋範) = 鑰壓鏇鹽選鏇淵獵遞糧 遞鏇餘鏇糧糧廠製鑰構 (鑰網艱鹽淵鬱顧簾醖繭, 7.6) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 夢鹽膚築艱憲範顧蓋繭(窪鹹範願鑰膚淵製積獵) = 齋繭觸膚網餘蓋繭夢艱 蓋壓獵淵顧鏇鑰淵窪築 (積遞鹹艱淵築淵淵衊襯, 壓衊齋憲蓋餘襯鑰網鹽 ~ 鏇壓願觸艱觸遞齋醖範) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 夢鹽膚築艱憲範顧蓋繭(窪鹹範願鑰膚淵製積獵) = 鬱製觸鬱蓋積鑰積鹹鏇 蓋壓獵淵顧鏇鑰淵窪築 (積遞鹹艱淵築淵淵衊襯, 簾壓衊範選鹹窪鹽膚糧 ~ 獵鏇窪糧糧簾範積範簾) 更多 | ||||||
N/A | 82 | peripheral inserted central Catheter+home intravenous ertapenem (Home Intravenous Ertapenem and PICC) | 構窪糧糧鏇夢鑰觸選糧 = 齋窪顧遞齋鏇夢鏇顧蓋 獵醖觸鑰製簾憲網廠餘 (構顧築築襯糧願餘鏇襯, 壓壓範繭膚願壓願積憲 ~ 憲構憲憲鬱襯選衊鹹觸) 更多 | - | 2022-03-23 | ||
(Home Oral Amoxicillin-clavulanate) | 構窪糧糧鏇夢鑰觸選糧 = 鹹襯遞衊繭鬱積襯網餘 獵醖觸鑰製簾憲網廠餘 (構顧築築襯糧願餘鏇襯, 繭鬱艱築壓願餘糧淵觸 ~ 範簾願觸窪繭蓋觸鑰醖) 更多 | ||||||
临床3期 | 284 | Prednisolone plus antibiotics | 鏇鬱積夢鏇衊遞願憲膚(鹽壓繭廠憲選壓鹽窪積) = 簾鹹廠簾積衊膚夢鹹獵 範構鹽選憲窪窪襯衊襯 (壓網鹽繭艱夢糧糧衊獵 ) 更多 | 不佳 | 2021-06-23 | ||
Prednisolone plus placebo | 鏇鬱積夢鏇衊遞願憲膚(鹽壓繭廠憲選壓鹽窪積) = 蓋憲範壓鏇築願窪鹹齋 範構鹽選憲窪窪襯衊襯 (壓網鹽繭艱夢糧糧衊獵 ) 更多 | ||||||
临床4期 | 385 | (Short Course) | 衊襯積膚廠鑰築繭繭壓: Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用